1
|
van der Knaap-Kind LS, Ombashi S, Van Roey V, Kragt L, Peterson P, Jabbari F, Wolvius EB, Versnel SL. Evaluation and recommendations of the oral health, oral function, and orofacial aesthetics-related measures of the ICHOM Standard Set for Cleft Lip and Palate. Int J Oral Maxillofac Surg 2024:S0901-5027(24)00001-8. [PMID: 38228465 DOI: 10.1016/j.ijom.2024.01.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2023] [Revised: 12/18/2023] [Accepted: 01/02/2024] [Indexed: 01/18/2024]
Abstract
This study was performed to evaluate the efficacy of outcome measures for the orofacial domain included in the International Consortium for Health Outcomes Measurement Standard Set for Cleft Lip and Palate (ICHOM-SCS). In this multicentre study involving two cleft centres, suggestions to optimize the type and timing of outcome measures were made based on data and clinical experience. Patient-reported outcome measures (PROMs) (CLEFT-Q Jaw, Teeth, Eating/Drinking; Child Oral Health Impact Profile-Oral Symptoms Scale (COHIP-OSS)) and clinical outcome measures (caries experience and dental occlusion) data were collected retrospectively for age 5, 8, 10, 12, 19, and 22 years. The data were categorized by cleft type and analysed within and between age groups using Spearman correlation, the distribution of responses per item, a two-sample test for equality of proportions, and effect plots. Most correlations between PROMs and clinical outcome measures were weak (r < 0.5), suggesting PROMs and clinical outcome measures complement each other. The COHIP-OSS and CLEFT-Q Eating/Drinking barely detected problems in any patient category and are no longer recommended. A suitable alternative appears complex to find; outcomes of this study and the recent literature doubt an added value. Similar problems were found in the CLEFT-Q Jaw at time-point 12 years. Therefore, time-points 15 and 17 years are currently suggested.
Collapse
Affiliation(s)
- L S van der Knaap-Kind
- Department of Oral and Maxillofacial Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.
| | - S Ombashi
- Department of Plastic and Reconstructive Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose And Throat Disorders, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - V Van Roey
- Department of Plastic and Reconstructive Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose And Throat Disorders, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - L Kragt
- Department of Oral and Maxillofacial Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - P Peterson
- Department of Reconstructive Plastic Surgery, Stockholm Craniofacial Team, Karolinska University Hospital, Stockholm, Sweden
| | - F Jabbari
- Department of Dental Medicine, Orthodontics and Paediatric Dentistry, Stockholm Craniofacial Team, Karolinska University Hospital, Stockholm, Sweden
| | - E B Wolvius
- Department of Oral and Maxillofacial Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose And Throat Disorders, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - S L Versnel
- Department of Plastic and Reconstructive Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; European Reference Network for Rare and/or Complex Craniofacial Anomalies and Ear, Nose And Throat Disorders, Erasmus University Medical Center, Rotterdam, the Netherlands
| |
Collapse
|
2
|
Rolfo C, Hess LM, Jen MH, Peterson P, Li X, Liu H, Lai Y, Sugihara T, Kiiskinen U, Vickers A, Summers Y. External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer. ESMO Open 2022; 7:100551. [PMID: 35930972 PMCID: PMC9434413 DOI: 10.1016/j.esmoop.2022.100551] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 06/24/2022] [Accepted: 06/28/2022] [Indexed: 11/25/2022] Open
Abstract
Background Data for selpercatinib [a selective REarranged during Transfection (RET) inhibitor] from a single-arm trial (LIBRETTO-001, NCT03157128) in RET-fusion-positive advanced/metastatic non-small-cell lung cancer (NSCLC) were used in combination with external data sources to estimate comparative efficacy [objective response rate (ORR), progression-free survival, and overall survival (OS)] in first- and second-line treatment settings. Methods Patient-level data were obtained from a de-identified real-world database. Patients diagnosed with advanced/metastatic NSCLC with no prior exposure to a RET inhibitor and one or more prior line of therapy were eligible. Additionally, individual patient-level data (IPD) were obtained from the pemetrexed + platinum arm of KEYNOTE-189 (NCT03950674, first line) and the docetaxel arm of REVEL (NCT01168973, post-progression). Patients were matched using entropy balancing, doubly robust method, and propensity score approaches. For patients with unknown/negative RET status, adjustment was made using a model fitted to IPD from a real-world database. Results In first-line unadjusted analyses of the real-world control, ORR was 87.2% for LIBRETTO-001 versus 66.7% for those with RET-positive NSCLC (P = 0.06). After adjustment for unknown RET status and other patient characteristics, selpercatinib remained significantly superior versus the real-world control for all outcomes (all P < 0.001 except unadjusted RET-fusion-positive cohort). Similarly, outcomes were significantly improved versus clinical trial controls (all P < 0.05). Conclusions Findings suggest improvement in outcomes associated with selpercatinib treatment versus the multiple external control cohorts, but should be interpreted with caution. Data were limited by the rarity of RET, lack of mature OS data, and uncertainty from assumptions to create control arms from external data. Single-arm trials are limited by the lack of a comparison arm, and external controls are needed. Multiple methodological approaches with various external control arms evaluated the comparative efficacy of selpercatinib. Findings suggest that selpercatinib is associated with significantly improved clinical outcomes versus standard therapies. Results should be considered exploratory and hypothesis generating due to the limitations of this study.
Collapse
Affiliation(s)
- C Rolfo
- Center for Thoracic Oncology at Tisch Cancer Center, Mount Sinai Health System & Icahn School of Medicine at Mount Sinai, New York
| | - L M Hess
- Eli Lilly and Company, Indianapolis, USA.
| | - M-H Jen
- Eli Lilly and Company, Basingstoke, UK
| | - P Peterson
- Eli Lilly and Company, Indianapolis, USA
| | - X Li
- Eli Lilly and Company, Indianapolis, USA
| | - H Liu
- Eli Lilly and Company, Indianapolis, USA
| | - Y Lai
- Eli Lilly and Company, Indianapolis, USA
| | | | | | | | - Y Summers
- The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
3
|
Schöffski P, Bahleda R, Wagner A, Burgess M, Junker N, Chisamore M, Peterson P, Ceccarelli M, William T. 154P Results of an open-label, phase Ia/Ib study of olaratumab plus pembrolizumab in patients with unresectable, locally advanced or metastatic soft tissue sarcoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
4
|
Winfree K, Molife C, Peterson P, Chen Y, Visseren C, Beyrer J, Leusch M, Dimou A. MO01.17 Real-World Characteristics and Outcomes of Advanced NSCLC Patients with Exon 19 or 21 EGFR Mutations. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2020.10.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Olsson E, Folkesson E, Peterson P, Önnerfjord P, Tjörnstrand J, Hughes HV, Englund M, Svensson J. Ultra-high field magnetic resonance imaging parameter mapping in the posterior horn of ex vivo human menisci. Osteoarthritis Cartilage 2019; 27:476-483. [PMID: 30552967 PMCID: PMC7610687 DOI: 10.1016/j.joca.2018.12.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/29/2018] [Revised: 11/26/2018] [Accepted: 12/03/2018] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To investigate the relationship between meniscus magnetic resonance (MR) relaxation parameters and meniscus degradation through quantitative imaging of ex vivo posterior horns of menisci from subjects with and without knee osteoarthritis (OA). DESIGN We sampled medial and lateral menisci from ten medial compartment knee OA patients (mean age 63 years) undergoing total knee replacement and from ten deceased donors (references, mean age 51 years). MR relaxation parameters T2*, T2 and T1 of the posterior horn were measured at a 9.4 T scanner. Comparisons were made between OA patients and references (with adjustment for age) as well as between medial and lateral menisci from the same knees. RESULTS Mean values (standard deviation) of mean T2* were 13 (3.8), 6.9 (2.3), 7.2 (1.9) and 7.2 (1.7) ms for the medial and lateral patient menisci and the medial and lateral reference menisci, respectively. Corresponding values were 17 (3.7), 9.0 (2.2), 12 (4) and 9.0 (1.3) ms for T2 and 1810 (150), 1630 (30), 1580 (90) and 1560 (50) ms for T1. All three relaxation times were significantly longer in medial OA menisci compared to the other groups. Among medial reference menisci, relaxation times (mainly T1) tended to increase with age. CONCLUSIONS MR relaxation times T2*, T2 and T1 in the posterior horn are longer in the medial menisci of patients with end-stage medial compartment knee OA compared to the corresponding lateral menisci and to reference menisci. The meniscus seems to undergo intrasubstance alterations related to both OA and ageing.
Collapse
Affiliation(s)
- E Olsson
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Malmö, Sweden,Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - E Folkesson
- Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden,Rheumatology and Molecular Skeletal Biology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - P Peterson
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Malmö, Sweden
| | - P Önnerfjord
- Rheumatology and Molecular Skeletal Biology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - J Tjörnstrand
- Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden,Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden
| | - HV Hughes
- Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - M Englund
- Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
| | - J Svensson
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Malmö, Sweden,Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden
| |
Collapse
|
6
|
Breathett K, Maffett S, Foraker R, Sturdivant R, Moon K, Hasan A, Franco V, Smith S, Lampert B, Emani S, Haas G, Kahwash R, Hershberger R, Binkley P, Helmkamp L, Colborn K, Peterson P, Sweitzer N, Abraham W. Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
7
|
Affiliation(s)
- N. Halecky
- University of California, Berkeley, Department of Nuclear Engineering Berkeley, California
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road Berkeley, California 94707
| | - J. Birkholzer
- Lawrence Berkeley National Laboratory, 1 Cyclotron Road Berkeley, California 94707
| | - P. Peterson
- University of California, Berkeley, Department of Nuclear Engineering Berkeley, California
| |
Collapse
|
8
|
Olson C, Rochau G, Slutz S, Morrow C, Olson R, Cuneo M, Hanson D, Bennett G, Sanford T, Bailey J, Stygar W, Vesey R, Mehlhorn T, Struve K, Mazarakis M, Savage M, Pointon T, Kiefer M, Rosenthal S, Cochrane K, Schneider L, Glover S, Reed K, Schroen D, Farnum C, Modesto M, Oscar D, Chhabildas L, Boyes J, Vigil V, Keith R, Turgeon M, Cipiti M, Lindgren E, Dandini V, Tran H, Smith D, McDaniel D, Quintenz J, Matzen MK, VanDevender JP, Gauster W, Shephard L, Walck M, Renk T, Tanaka T, Ulrickson M, Meier W, Latkowski J, Moir R, Schmitt R, Reyes S, Abbott R, Peterson R, Pollock G, Ottinger P, Schumer J, Peterson P, Kammer D, Kulcinski G, El-Guebaly L, Moses G, Sviatoslavsky I, Sawan M, Anderson M, Bonazza R, Oakley J, Meekunasombat P, De Groot J, Jensen N, Abdou M, Ying A, Calderoni P, Morley N, Abdel-Khalik S, Dillon C, Lascar C, Sadowski D, Curry R, McDonald K, Barkey M, Szaroletta W, Gallix R, Alexander N, Rickman W, Charman C, Shatoff H, Welch D, Rose D, Panchuk P, Louie D, Dean S, Kim A, Nedoseev S, Grabovsky E, Kingsep A, Smirnov V. Development Path for Z-Pinch IFE. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-a757] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C. Olson
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - G. Rochau
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - S. Slutz
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - C. Morrow
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - R. Olson
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Cuneo
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - D. Hanson
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - G. Bennett
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - T. Sanford
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - J. Bailey
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - W. Stygar
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - R. Vesey
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - T. Mehlhorn
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - K. Struve
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Mazarakis
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Savage
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - T. Pointon
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Kiefer
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - S. Rosenthal
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - K. Cochrane
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - L. Schneider
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - S. Glover
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - K. Reed
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - D. Schroen
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - C. Farnum
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Modesto
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - D. Oscar
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - L. Chhabildas
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - J. Boyes
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - V. Vigil
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - R. Keith
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Turgeon
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Cipiti
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - E. Lindgren
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - V. Dandini
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - H. Tran
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - D. Smith
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - D. McDaniel
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - J. Quintenz
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. K. Matzen
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | | | - W. Gauster
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - L. Shephard
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Walck
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - T. Renk
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - T. Tanaka
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - M. Ulrickson
- Sandia National Laboratories, Albuquerque, NM 87107 USA
| | - W. Meier
- Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| | - J. Latkowski
- Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| | - R. Moir
- Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| | - R. Schmitt
- Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| | - S. Reyes
- Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| | - R. Abbott
- Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| | - R. Peterson
- Los Alamos National Laboratories, Los Alamos, NM 87545, USA
| | - G. Pollock
- Los Alamos National Laboratories, Los Alamos, NM 87545, USA
| | - P. Ottinger
- Naval Research Laboratory, Washington, DC 20375, USA
| | - J. Schumer
- Naval Research Laboratory, Washington, DC 20375, USA
| | - P. Peterson
- University of California, Berkeley, CA 94720, USA
| | - D. Kammer
- University of Wisconsin, Madison, WI 53706, USA
| | | | | | - G. Moses
- University of Wisconsin, Madison, WI 53706, USA
| | | | - M. Sawan
- University of Wisconsin, Madison, WI 53706, USA
| | - M. Anderson
- University of Wisconsin, Madison, WI 53706, USA
| | - R. Bonazza
- University of Wisconsin, Madison, WI 53706, USA
| | - J. Oakley
- University of Wisconsin, Madison, WI 53706, USA
| | | | - J. De Groot
- University of California, Davis, Davis, CA 95616, USA
| | - N. Jensen
- University of California, Davis, Davis, CA 95616, USA
| | - M. Abdou
- University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - A. Ying
- University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - P. Calderoni
- University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - N. Morley
- University of California, Los Angeles, Los Angeles, CA 90095, USA
| | - S. Abdel-Khalik
- Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - C. Dillon
- Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - C. Lascar
- Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - D. Sadowski
- Georgia Institute of Technology, Atlanta, Georgia 30332, USA
| | - R. Curry
- University of Missouri-Columbia, Columbia, MO 65211, USA
| | - K. McDonald
- University of Missouri-Columbia, Columbia, MO 65211, USA
| | - M. Barkey
- University of Alabama, Tuscaloosa, AL 35487, USA
| | - W. Szaroletta
- University of New Mexico, Albuquerque, NM 87106, USA
| | - R. Gallix
- General Atomics, San Diego, CA 92121, USA
| | | | - W. Rickman
- General Atomics, San Diego, CA 92121, USA
| | - C. Charman
- General Atomics, San Diego, CA 92121, USA
| | - H. Shatoff
- General Atomics, San Diego, CA 92121, USA
| | - D. Welch
- ATK Mission Research, Albuquerque, NM 87110, USA
| | - D. Rose
- ATK Mission Research, Albuquerque, NM 87110, USA
| | | | - D. Louie
- Omicron, Albuquerque, NM 87110, USA
| | - S. Dean
- Fusion Power Associates, Gaithersburg, MD 20879, USA
| | - A. Kim
- Institute of High Current Electronics, Tomsk, Russia
| | | | | | | | | |
Collapse
|
9
|
Wong C, Malang S, Sawan M, Smolentsev S, Majumdar S, Merrill B, Sze DK, Morley N, Sharafat S, Dagher M, Peterson P, Zhao H, Zinkle SJ, Abdou M, Youssef M. Assessment of First Wall and Blanket Options with the Use of Liquid Breeder. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-a734] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C.P.C. Wong
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - S. Malang
- Fusion Nuclear Technology Consulting, Linkenheim, Germany
| | - M Sawan
- University of Wisconsin, Madison, Wisconsin
| | | | - S. Majumdar
- Argonne National Laboratory, Argonne, Illinois
| | | | - D. K. Sze
- University of California, San Diego, California
| | - N. Morley
- University of California, Los Angeles, California
| | - S Sharafat
- University of California, Los Angeles, California
| | - M. Dagher
- University of California, Los Angeles, California
| | - P. Peterson
- University of California, Berkeley, California
| | - H Zhao
- University of California, Berkeley, California
| | - S. J. Zinkle
- Oak Ridge National Laboratory, Oak Ridge, Tennessee
| | - M. Abdou
- University of California, Los Angeles, California
| | - M Youssef
- University of California, Los Angeles, California
| |
Collapse
|
10
|
Breathett K, Liu W, Allen L, Daugherty S, Blair I, Jones J, Grunwald G, Moss M, Kiser T, Burnham E, Vandivier R, Clark B, Lewis E, Mazimba S, Ho P, Peterson P. Racial Differences in Receipt of Care by a Cardiologist During a Critical Heart Failure Admission. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
11
|
Regnell SE, Peterson P, Trinh L, Broberg P, Leander P, Lernmark Å, Månsson S, Elding Larsson H. Pancreas volume and fat fraction in children with Type 1 diabetes. Diabet Med 2016; 33:1374-9. [PMID: 26996278 DOI: 10.1111/dme.13115] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/14/2016] [Indexed: 12/11/2022]
Abstract
AIMS People with Type 1 diabetes have smaller pancreases than healthy individuals. Several diseases causing pancreatic atrophy are associated with pancreatic steatosis, but pancreatic fat in Type 1 diabetes has not been measured. This cross-sectional study aimed to compare pancreas size and fat fraction in children with Type 1 diabetes and controls. METHODS The volume and fat fraction of the pancreases of 22 children with Type 1 diabetes and 29 controls were determined using magnetic resonance imaging. RESULTS Pancreas volume was 27% smaller in children with diabetes (median 34.9 cm(3) ) than in controls (47.8 cm(3) ; P < 0.001). Pancreas volume correlated positively with age in controls (P = 0.033), but not in children with diabetes (P = 0.649). Pancreas volume did not correlate with diabetes duration, but it did correlate positively with units of insulin/kg body weight/day (P = 0.048). A linear model of pancreas volume as influenced by age, body surface area and insulin units/kg body weight/day found that insulin dosage correlated with pancreas volume after controlling for both age and body surface area (P = 0.009). Pancreatic fat fraction was not significantly different between the two groups (1.34% vs. 1.57%; P = 0.891). CONCLUSIONS Our findings do not indicate that pancreatic atrophy in Type 1 diabetes is associated with an increased pancreatic fat fraction, unlike some other diseases featuring reduced pancreatic volume. We speculate that our results may support the hypotheses that much of pancreatic atrophy in Type 1 diabetes occurs before the clinical onset of the disease and that exogenous insulin administration decelerates pancreatic atrophy after diabetes onset.
Collapse
Affiliation(s)
- S E Regnell
- Pediatric Endocrinology, Diabetes and Celiac Disease Unit, Lund University/Clinical Research Centre and Skåne University Hospital, Malmö.
| | - P Peterson
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö
| | - L Trinh
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö
| | - P Broberg
- Department of Cancer Epidemiology, Department of Clinical Sciences, Lund University and Skåne University Hospital, Lund
| | - P Leander
- Department of Radiology, Department of Translational Medicine, Lund University and Skåne University Hospital, Malmö, Sweden
| | - Å Lernmark
- Pediatric Endocrinology, Diabetes and Celiac Disease Unit, Lund University/Clinical Research Centre and Skåne University Hospital, Malmö
| | - S Månsson
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Skåne University Hospital, Malmö
| | - H Elding Larsson
- Pediatric Endocrinology, Diabetes and Celiac Disease Unit, Lund University/Clinical Research Centre and Skåne University Hospital, Malmö
| |
Collapse
|
12
|
Wolff ASB, Sarkadi AK, Maródi L, Kärner J, Orlova E, Oftedal BEV, Kisand K, Oláh E, Meloni A, Myhre AG, Husebye ES, Motaghedi R, Perheentupa J, Peterson P, Willcox N, Meager A. Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood. J Clin Immunol 2013; 33:1341-8. [PMID: 24158785 DOI: 10.1007/s10875-013-9938-6] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2013] [Accepted: 09/02/2013] [Indexed: 01/30/2023]
Abstract
PURPOSE Almost all patients with autoimmune polyendocrine syndrome (APS)-I have high titer neutralizing autoantibodies to type I interferons (IFN), especially IFN-ω and IFN-α2, whatever their clinical features and onset-ages. About 90 % also have antibodies to interleukin (IL)-17A, IL-17F and/or IL-22; they correlate with the chronic mucocutaneous candidiasis (CMC) that affects ~90 % of patients. Our aim was to explore how early the manifestations and endocrine and cytokine autoantibodies appear in young APS-I patients. That may hold clues to very early events in the autoimmunization process in these patients. METHODS Clinical investigations and autoantibody measurements in 13 APS-I patients sampled before age 7 years, and 3 pre-symptomatic siblings with AIRE-mutations in both alleles. RESULTS Antibody titers were already high against IFN-α2 and IFN-ω at age 6 months in one sibling-8 months before onset of APS-I-and also against IL-22 at 7 months in another (still unaffected at age 5 years). In 12 of the 13 APS-I patients, antibody levels were high against IFN-ω and/or IL-22 when first tested, but only modestly positive against IFN-ω in one patient who had only hypo-parathyroidism. Endocrine organ-specific antibodies were present at age 6 months in one sibling, and as early as 36 and 48 months in two of the six informative subjects. CONCLUSION This is the first study to collate the onset of clinical features, cytokine and endocrine autoantibodies in APS-I infants and siblings. The highly restricted early autoantibody responses and clinical features they show are not easily explained by mere loss of broad-specific self-tolerance inducing mechanisms, but hint at some more sharply focused early event(s) in autoimmunization.
Collapse
Affiliation(s)
- A S B Wolff
- Department of Clinical Science, University of Bergen, Laboratory building, 8th floor, 5021, Bergen, Norway,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Kärner J, Meager A, Laan M, Maslovskaja J, Pihlap M, Remm A, Juronen E, Wolff ASB, Husebye ES, Podkrajšek KT, Bratanic N, Battelino T, Willcox N, Peterson P, Kisand K. Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice. Clin Exp Immunol 2013; 171:263-72. [PMID: 23379432 PMCID: PMC3569533 DOI: 10.1111/cei.12024] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/29/2012] [Indexed: 12/13/2022] Open
Abstract
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a recessive disorder resulting from mutations in the autoimmune regulator (AIRE). The patients' autoantibodies recognize not only multiple organ-specific targets, but also many type I interferons (IFNs) and most T helper type 17 (Th17) cell-associated cytokines, whose biological actions they neutralize in vitro. These anti-cytokine autoantibodies are highly disease-specific: otherwise, they have been found only in patients with thymomas, tumours of thymic epithelial cells that fail to express AIRE. Moreover, autoantibodies against Th17 cell-associated cytokines correlate with chronic mucocutaneous candidiasis in both syndromes. Here, we demonstrate that the immunoglobulin (Ig)Gs but not the IgAs in APECED sera are responsible for neutralizing IFN-ω, IFN-α2a, interleukin (IL)-17A and IL-22. Their dominant subclasses proved to be IgG1 and, surprisingly, IgG4 without IgE, possibly implicating regulatory T cell responses and/or epithelia in their initiation in these AIRE-deficiency states. The epitopes on IL-22 and IFN-α2a appeared mainly conformational. We also found mainly IgG1 neutralizing autoantibodies to IL-17A in aged AIRE-deficient BALB/c mice - the first report of any target shared by these human and murine AIRE-deficiency states. We conclude that autoimmunization against cytokines in AIRE deficiency is not simply a mere side effect of chronic mucosal Candida infection, but appears to be related more closely to disease initiation.
Collapse
Affiliation(s)
- J. Kärner
- Molecular Pathology Group, Institute of Biomedicine, University of TartuTartu, Estonia
| | - A. Meager
- Biotherapeutics, National Institute for Biological Standards and ControlSouth Mimms, UK
| | - M. Laan
- Molecular Pathology Group, Institute of Biomedicine, University of TartuTartu, Estonia
| | - J. Maslovskaja
- Molecular Pathology Group, Institute of Biomedicine, University of TartuTartu, Estonia
| | - M. Pihlap
- Molecular Pathology Group, Institute of Biomedicine, University of TartuTartu, Estonia
| | - A. Remm
- Molecular Pathology Group, Institute of Biomedicine, University of TartuTartu, Estonia
| | - E. Juronen
- Immune Analyze Group, Institute of Biomedicine, University of TartuTartu, Estonia
| | - A. S. B. Wolff
- Institute of Medicine, University of BergenBergen, Norway
| | - E. S. Husebye
- Institute of Medicine, University of BergenBergen, Norway
| | - K. T. Podkrajšek
- Centre for Medical Genetics, University Children's HospitalLjubljana, Slovenia
| | - N. Bratanic
- Centre for Medical Genetics, University Children's HospitalLjubljana, Slovenia
| | - T. Battelino
- Centre for Medical Genetics, University Children's HospitalLjubljana, Slovenia
| | - N. Willcox
- Neurosciences Group, Weatherall Institute of Molecular Medicine, University of OxfordOxford, UK
| | - P. Peterson
- Molecular Pathology Group, Institute of Biomedicine, University of TartuTartu, Estonia
| | - K. Kisand
- Molecular Pathology Group, Institute of Biomedicine, University of TartuTartu, Estonia
- Immunology Group, Institute of Biomedicine, University of TartuTartu, Estonia
| |
Collapse
|
14
|
Zentner MD, Pomeroy G, Bari RA, Cojazzi GGM, Haas E, Killeen T, Peterson P, Whitlock JJ, Wonder EF. Interpretation and Use of the Results of Proliferation Resistance Studies. NUCL TECHNOL 2012. [DOI: 10.13182/nt12-a14071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Michael D. Zentner
- Pacific Northwest National Laboratory, 902 Battelle Boulevard, Richland Washington 99352
| | - George Pomeroy
- U.S. Department of Energy, National Nuclear Security Administration, Washington, D.C
| | | | | | - Eckhart Haas
- International Atomic Energy Agency, Wagramer Strasse 5, P.O. Box 100 A-1400 Vienna, Austria
| | - Thomas Killeen
- International Atomic Energy Agency, Wagramer Strasse 5, P.O. Box 100 A-1400 Vienna, Austria
| | - P. Peterson
- University of California, Berkeley, California 94720
| | - Jeremy J. Whitlock
- Atomic Energy of Canada Limited, Chalk River Laboratories, Chalk River, Ontario Canada K0J 1J0
| | | |
Collapse
|
15
|
Matar HE, Peterson P, Sangle S, D'Cruz DP. Correlation of 24-hour urinary protein quantification with spot urine protein:creatinine ratio in lupus nephritis. Lupus 2012; 21:836-9. [PMID: 22331194 DOI: 10.1177/0961203312437438] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVES Twenty-four hour urine collection has been the foundation for monitoring patients with lupus nephritis. However, the use of protein to creatinine ratios in spot urine samples is now widely used. We aimed to evaluate the validity of this method cross-sectionally and longitudinally. METHODS A cross-sectional retrospective study was conducted. Records of 486 lupus nephritis patients were searched for paired results of 24-h quantification of urinary protein and a random spot urine protein to creatinine ratio and were examined over a three-year period. RESULTS AND CONCLUSIONS Ninety-five lupus nephritis patients had paired results and were included in the final analysis, male/female 14/81, mean age 36.5 years. Over a three-year period there were a total of 137 samples from 95 patients. For the entire dataset, there was a significant correlation between protein:creatinine ratio and 24-h urine collection protein (mg), Spearman Rho correlation coefficient was 0.869, p < 0.0001 with (R (2 )= 0.504). There was also a strong correlation for longitudinal data, n = 14 at two-years Rho 0.910, p < 0.0001 with (R (2 )= 0.878), n = 8 at three-years Rho 0.909, p < 0.0001 and (R (2 )= 0.73). We have shown for the first time in a UK population of lupus nephritis patients, well trained in producing 24-h collection, that the spot protein:creatinine ratio correlates well with 24-h urinary total protein excretion. Having a simple, reliable, reproducible and cost-effective test such as the spot urine protein:creatinine ratio is therefore a valuable tool with which to monitor disease progression.
Collapse
Affiliation(s)
- H E Matar
- Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
| | | | | | | |
Collapse
|
16
|
Abstract
We derive equations for the ASE intensity, decay time, and heat load. The crux of our development is frequency integration over the gain lineshape followed by a spatial integration over the emitters. These integrations result in a gain length that is determined from experiment. We measure the gain as a function of incident pump power for a multi-pass pumped Yb:YAG disk doped at 9.8 at.% with an anti-ASE cap. The incident pump powers are up to 3kW. Our fit to the measured gain is within 10% of the measured gain up to pump powers where the gain starts to flatten out and roll over. In this comparison we extract the gain length that turns out to be 43% of the pump spot size of 7mm.
Collapse
Affiliation(s)
- P Peterson
- Boeing LTS Inc., Kirtland Air Force Base, NM, USA
| | | | | | | | | |
Collapse
|
17
|
Peterson P, Templeton R, Kademani D. Poster 60: Metastatic Adenocarcinoma of the TMJ: A Report of 2 Cases and Review of the Literature. J Oral Maxillofac Surg 2011. [DOI: 10.1016/j.joms.2011.06.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
Laasmaa M, Vendelin M, Peterson P. Application of regularized Richardson-Lucy algorithm for deconvolution of confocal microscopy images. J Microsc 2011; 243:124-40. [PMID: 21323670 PMCID: PMC3222693 DOI: 10.1111/j.1365-2818.2011.03486.x] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2010] [Accepted: 01/03/2011] [Indexed: 12/05/2022]
Abstract
Although confocal microscopes have considerably smaller contribution of out-of-focus light than widefield microscopes, the confocal images can still be enhanced mathematically if the optical and data acquisition effects are accounted for. For that, several deconvolution algorithms have been proposed. As a practical solution, maximum-likelihood algorithms with regularization have been used. However, the choice of regularization parameters is often unknown although it has considerable effect on the result of deconvolution process. The aims of this work were: to find good estimates of deconvolution parameters; and to develop an open source software package that would allow testing different deconvolution algorithms and that would be easy to use in practice. Here, Richardson-Lucy algorithm has been implemented together with the total variation regularization in an open source software package IOCBio Microscope. The influence of total variation regularization on deconvolution process is determined by one parameter. We derived a formula to estimate this regularization parameter automatically from the images as the algorithm progresses. To assess the effectiveness of this algorithm, synthetic images were composed on the basis of confocal images of rat cardiomyocytes. From the analysis of deconvolved results, we have determined under which conditions our estimation of total variation regularization parameter gives good results. The estimated total variation regularization parameter can be monitored during deconvolution process and used as a stopping criterion. An inverse relation between the optimal regularization parameter and the peak signal-to-noise ratio of an image is shown. Finally, we demonstrate the use of the developed software by deconvolving images of rat cardiomyocytes with stained mitochondria and sarcolemma obtained by confocal and widefield microscopes.
Collapse
Affiliation(s)
- M Laasmaa
- Laboratory of Systems Biology, Institute of Cybernetics, Tallinn University of Technology, Tallinn, Estonia
| | | | | |
Collapse
|
19
|
Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P. Prognostic factors of overall survival in head and neck cancer: Post-hoc exploratory results from the SPINNAKER trial—A phase III randomized clinical trial of pemetrexed plus cisplatin versus cisplatin monotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Worlton T, Chatterjee A, Hammonds J, Bouzek C, Mikkelson D, Mikkelson R, Miller M, Serum B, Peterson P. Scientific Review: New Software for Neutron Scattering Data Visualization. ACTA ACUST UNITED AC 2010. [DOI: 10.1080/00323910490970690] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Sprague M, Smith A, Regen L, Williams R, McKinney S, Peterson P, Kellum C, Pereira S. 9-W: Identification of a novel HLA-B*27/44 hybrid allele. Hum Immunol 2009. [DOI: 10.1016/j.humimm.2009.09.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, Wu YL, Peterson P, Krejcy K, Zielinski C. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.18_suppl.cra8000] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA8000 Background: Pemetrexed's efficacy, favorable tolerability profile, and ease of administration provided a strong rationale for evaluation as maintenance therapy in patients (pts) with advanced NSCLC. We present the final analyses for all outcomes, including overall survival (OS), from a phase III study of Pem vs. Plac (Ciuleanu, J Clin Oncol 26, 2008, A 8011) in pts with stage IIIB/IV NSCLC who had not progressed on four cycles of platinum-based chemotherapy. Methods: In this double-blind trial, pts were randomized 2:1 to receive Pem (500 mg/m2, day 1) plus BSC or Plac plus BSC in 21-day cycles until disease progression. All pts received vitamin B12, folic acid, and dexamethasone. The final OS analysis was performed using an unadjusted Cox model. Overall α = 0.05 for PFS and OS. Results: In the 663 randomized pts (Pem 441: Plac 222), Pem resulted in significantly better OS (13.4 vs. 10.6 mos [HR 0.79, 95% CI: 0.65–0.95, P = 0.012]). As reported earlier, Pem also had better PFS (P <0.00001) and response (P <0.001) ( Table ). The improvements in PFS and OS were observed primarily in patients with non-squamous histology (PFS HR = 0.47 and OS HR = 0.70). Treatment by histology interaction for OS was significant (P = 0.038). Drug-related grade 3/4 toxicities were higher for Pem (16% vs 4%; P <0.001); specifically, fatigue (5% vs 0.5%) and neutropenia (2.9% vs. 0%). Grade 3/4 toxicities did not increase significantly in pts who received ≥6 and ≥10 cycles of Pem. There were no Pem-related deaths. Fewer pts in the Pem arm (51.5% vs 67.1%; P <0.001) received systemic post-discontinuation therapy. Conclusions: Pem maintenance therapy is well tolerated and offers superior OS and PFS compared with Plac, making it a new treatment paradigm for patients with advanced NSCLC who respond to initial therapy. This trial further validates that Pem has greater efficacy in patients with non-squamous histology. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- C. P. Belani
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - T. Brodowicz
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - T. Ciuleanu
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - J. H. Kim
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - M. Krzakowski
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - E. Laack
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - Y. L. Wu
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - P. Peterson
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - K. Krejcy
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| | - C. Zielinski
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University of Vienna, General Hospital of Vienna, and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria
| |
Collapse
|
23
|
Belani CP, Brodowicz T, Ciuleanu T, Kim JH, Krzakowski M, Laack E, Wu YL, Peterson P, Krejcy K, Zielinski C. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.cra8000] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA8000 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
Collapse
Affiliation(s)
- C. P. Belani
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - T. Brodowicz
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - T. Ciuleanu
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - J. H. Kim
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - M. Krzakowski
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - E. Laack
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - Y. L. Wu
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - P. Peterson
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - K. Krejcy
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| | - C. Zielinski
- Penn State Hershey Cancer Institute, Hershey, PA; Medical University Vienna General Hospital and CECOG, Vienna, Austria; Oncology Institute Ion Chiricuta and CECOG, Cluj, Romania; Yonsei Cancer Center, Seoul, Republic of Korea; Centre of Oncology-Institute and CECOG, Warsaw, Poland; University Cancer Center Hamburg, Eppendorf, Germany; Guangdong Province People's Hospital, Guangzhou, China; Eli Lilly and Company, Indianapolis, IN; Eli Lilly Regional Operations, Vienna, Austria; Medical University of
| |
Collapse
|
24
|
Abstract
A pool of immature T cells with a seemingly unrestricted repertoire of antigen specificities is generated life-long in the thymus. Amongst these cells are, however, thymocytes that express a strongly self-reactive antigen receptor and hence hold the potential to trigger autoimmunity. To prevent such an outcome, the thymus employs several independent but functionally related strategies that act in parallel to enforce self-tolerance. The deletion of strongly self-reactive thymocytes and the generation of regulatory T cells constitute the two most efficient mechanisms to induce and maintain immunological tolerance. Thymic epithelial cells of the medulla express for this purpose tissue-restricted self-antigens. This review will focus on the cellular and molecular mechanisms operative in the thymus to shape a repertoire of mature T cells tolerant to self-antigens.
Collapse
Affiliation(s)
- G A Holländer
- Department of Clinical-Biological Sciences, Laboratory of Pediatric Immunology, Center for Biomedicine, University of Basel and The University Children's Hospital, Switzerland.
| | | |
Collapse
|
25
|
Meager A, Peterson P, Willcox N. Hypothetical review: thymic aberrations and type-I interferons; attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol 2008; 154:141-51. [PMID: 18727623 DOI: 10.1111/j.1365-2249.2008.03739.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
In sporadic autoimmune disorders, dendritic cells are increasingly being incriminated as agents provocateurs. However, the mechanisms and any 'danger signals' that induce them to autoimmunize remain enigmatic. Here, we focus on unexpected clues from two prototypic/ highly informative autoimmune syndromes, acquired thymoma-associated myasthenia gravis and the monogenic autoimmune polyendocrine syndrome type-1 (APS1), caused by mutations in the AutoImmune Regulator (AIRE). Both involve the thymus, and in both we find early, persistent, highly prevalent and high-titre neutralizing autoantibodies against type-I interferons, regardless of the exact AIRE genotype or the characteristically variable clinical phenotype in APS1. Thus these key innate<-->adaptive immune intermediaries are now implicated in APS1 and paraneoplastic myasthenia as well as in systemic lupus erythematosus and other sporadic autoimmune disorders. The currently accepted notion that autoimmunization proceeds automatically (by 'default') does not explain how, when or where autoimmune responses are initiated against which targets in APS1, or whether exogenous or internal danger signals are involved, or predict whether the primary auto-immunogenic targets are AIRE-dependent. As the parallels between these syndromes must hold novel clues to these puzzles, they demand explanations. To unify these and other findings, we propose that autoimmunization occurs centrally in aberrant thymic environments rendered 'dangerous' by AIRE-deficiency (possibly by excess undegraded nucleic acids/dead cell debris). The ensuing autoreactivity focuses early on the locally abundant type I interferons and then on other peripheral tissue autoantigens that are still expressed despite the absence of AIRE. These ideas raise numerous questions that others may already have the materials to address.
Collapse
Affiliation(s)
- A Meager
- Biotherapeutics, National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potter's Bar, Herts, UK
| | | | | |
Collapse
|
26
|
Ciuleanu TE, Brodowicz T, Belani CP, Kim J, Krzakowski M, Laack E, Wu Y, Peterson P, Adachi S, Zielinski CC. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8011] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Zielinski CC, Yang S, Santoro A, Ramlau R, Liepa AM, Peterson P, Brodowicz T, Madhavan J, Franke FA, Cucevic B. Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-small cell lung cancer: Evidence from a large randomized study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Cullen M, Zatloukal P, Sörenson S, Novello S, Fischer J, Joy A, Zereu M, Peterson P, Visseren-Grul C, Iscoe N. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008; 19:939-45. [DOI: 10.1093/annonc/mdm592] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Gombos Z, Hermann R, Kiviniemi M, Nejentsev S, Reimand K, Fadeyev V, Peterson P, Uibo R, Ilonen J. Analysis of extended human leukocyte antigen haplotype association with Addison's disease in three populations. Eur J Endocrinol 2007; 157:757-61. [PMID: 18057383 DOI: 10.1530/eje-07-0290] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Addison's disease is an organ-specific autoimmune disorder with a polygenic background. The aim of the study was to identify non-class II human leukocyte antigen (HLA) susceptibility genes for Addison's disease. DESIGN AND METHODS Addison's disease patients from three European populations were analysed for selected HLA-DR-DQ alleles and for 11 microsatellite markers covering approximately 4 Mb over the HLA region. Subjects were 69 patients with Addison's disease from Estonia (24), Finland (14) and Russia (31). Consecutively recruited healthy newborns from the same geographical regions were used as controls (269 Estonian, 1000 Finnish and 413 Russian). Association measures for HLA-DRB1, DQB1, DQA1 and 11 microsatellites between D6S273 and D6S2223 were taken. A low-resolution full-house typing was used for HLA class II genes, while microsatellite markers were studied using fluorescence-based DNA fragment sizing technology. RESULTS We confirmed that the HLA-DR3-DQ2 and the DQB1*0302-DRB1*0404 haplotypes confer disease susceptibility. In Russian patients, we also found an increase of DRB1*0403 allele, combined with DQB1*0305 allele in three out of six cases (P<0.0001). Analysis of 11 microsatellite markers including STR MICA confirmed the strong linkage in DR3-DQ2 haplotypes but DRB1*0404-DQB1*0302 haplotypes were diverse. MICA5.1 allele was found in 22 out of 24 Estonian patients, but results from Finnish and Russian patients did not support its independent role in disease susceptibility. CONCLUSION HLA-DRB1*0403 was identified as a novel susceptibility allele for Addison's disease. Additionally, we found no evidence of a non-class II HLA disease susceptibility locus; however, the HLA-DR3-DQ2 haplotype appeared more conserved in patient groups with high DR-DQ2 frequencies.
Collapse
Affiliation(s)
- Z Gombos
- Immunogenetics Laboratory, University of Turku, Medicity, Tykistökatu 6 A 4th, 20520 Turku, Finland.
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Reimand K, Perheentupa J, Link M, Krohn K, Peterson P, Uibo R. Testis-expressed protein TSGA10 - an auto-antigen in autoimmune polyendocrine syndrome type I. Int Immunol 2007; 20:39-44. [DOI: 10.1093/intimm/dxm118] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Scagliotti G, Park K, Patil S, Rolski J, Gorksel T, Gans S, Martins R, Visseren-Grul C, Peterson P. 6519 ORAL Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71347-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
32
|
Cullen M, Zatloukal P, Sörenson S, Novello S, Fischer JR, Joy A, Zereu M, Peterson P, Visseren-Grul C, Iscoe N. Pemetrexed in advanced non-small cell lung cancer: A randomized trial of 500 mg/m2 vs 900 mg/m2 in 588 patients who progressed after platinum-containing chemotherapy. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.lba7727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA7727 Introduction: The mild toxicity profile of pemetrexed (P), seen in a phase III trial of P 500 mg/m2 vs docetaxel 75 mg/m2 in vitamin-supplemented patients (pts), suggests higher doses of P can be given in pts with previously treated advanced non-small cell lung cancer (NSCLC) without significant toxicity. We conducted a phase III trial to determine if a higher dose of P (900 mg/m2) could improve survival vs the standard P dose in pts with NSCLC. Methods: Pts with stage III/IV NSCLC, previously treated with platinum-based chemotherapy, were randomized to P 500 or 900 mg/m2 iv q3week. After the second planned interim analysis, the Data Safety Monitoring Board recommended discontinuation of enrollment due to low probability of demonstrating a survival advantage and a greater incidence of some toxicities on the P 900 arm. Patients were allowed to continue treatment at the P 500 dose. Results: 588 randomized pts were evaluated for efficacy and 581 pts, who received =1 dose, for safety. Safety data for pts who transitioned from P 900 to P 500 were analyzed separately. The treatment arms were balanced regarding baseline characteristics and prior treatment. Both arms had: ∼67% males, median age 62 yrs, 87% pts with an ECOG PS of 0 or 1, and 77% pts with stage IV disease. Key results are shown in the table . There was no statistical difference between arms for any efficacy measure. In general, the incidence of adverse events (AEs) was comparable or numerically higher in the P 900 arm. Some AEs (all grades) reported a >5% difference between the P 900 (N=240) and P 500 arms: fatigue (41.7% vs 32.8%), anemia (32.9% vs 22.1%), vomiting (20.0% vs 13.1%), stomatitis (17.9% vs 10.0%), diarrhea (15.4% vs 10.0%), and thrombocytopenia (11.3% vs 5.5%). Conclusion: P 900 offers no advantage over P 500 mg/m2 as second-line therapy for pts with advanced NSCLC. Certain toxicities were somewhat more pronounced in the P 900 group. No significant financial relationships to disclose. [Table: see text]
Collapse
Affiliation(s)
- M. Cullen
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - P. Zatloukal
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - S. Sörenson
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - S. Novello
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - J. R. Fischer
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - A. Joy
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - M. Zereu
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - P. Peterson
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - C. Visseren-Grul
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| | - N. Iscoe
- University Hospital Birmingham, Birmingham, United Kingdom; Charles University, Prague, Czech Republic; University Hospital, Linkoping, Sweden; Ospedale S Luigi, Orbassano, Torino, Italy; Klinik Loewenstein, Loewenstein, Germany; Cross Cancer Institute, Edmonton, AB, Canada; Santa Casa de Porto Alegre, Porto Alegre, Brazil; Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
33
|
Ströbel P, Murumägi A, Klein R, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Müller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 2007; 211:563-571. [PMID: 17334980 DOI: 10.1002/path.2141] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2006] [Accepted: 12/21/2006] [Indexed: 01/12/2023]
Abstract
Thymomas are thymic epithelial neoplasms, associated with a variety of autoimmune disorders (especially myasthenia gravis), that apparently result from aberrant intra-tumourous thymopoiesis and export of inefficiently tolerized T-cells to the periphery. The autoimmune regulator (AIRE) drives the expression of self-antigens in the thymic medulla and plays an essential role in 'central' tolerance in both humans and mice. However, while inactivating AIRE mutations result in the 'autoimmune polyendocrinopathy syndrome type 1' (APS-1), its major features are not well reproduced in AIRE-knock-out mice. Therefore, alternative human disease scenarios with concomitant AIRE deficiency may be valuable tools to test conclusions drawn from mouse models. Here we show, in a large series, that approximately 95% of thymoma patients are 'chimeric'; expression of AIRE and major AIRE-related autoantigens (eg insulin) were undetectable in their tumours but maintained in their remnant thymic tissue and lymph nodes. Notably, despite the AIRE-deficient thymopoiesis in thymomas, disorders and autoantibodies typical of APS-1 were distinctly uncommon in these patients. The one striking similarity was in the recently observed neutralizing anti-type I interferon (IFN) antibodies, which are found at diagnosis in 100% of patients with APS-1 and in approximately 60% of patients with thymomas, as we show here. We conclude that APS-1 type autoantigens must be protected from autoimmunity by mechanisms that do not extend to the muscle autoantigens so frequently targeted in thymoma patients but so rarely recognized in APS-1. Thus our findings argue strongly for a tolerogenic function of AIRE beyond its role in negative T-cell selection in human thymopoiesis, and/or for specific autoimmunization against muscle in thymomas.
Collapse
Affiliation(s)
- P Ströbel
- Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Germany
| | - A Murumägi
- Institute of Medical Technology, Tampere, Finland
| | - R Klein
- Department of Internal Medicine II, University of Tübingen, Germany
| | - M Luster
- Department of Nuclear Medicine, University of Würzburg, Germany
| | - M Lahti
- Institute of Medical Technology, Tampere, Finland
| | - K Krohn
- Institute of Medical Technology, Tampere, Finland
| | - B Schalke
- Department of Neurology, University of Regensburg, Germany
| | - W Nix
- Department of Neurology, University of Mainz, Germany
| | - R Gold
- Department of Neurology, University of Göttingen, Germany
| | - P Rieckmann
- Department of Neurology, University of Würzburg, Germany
| | - K Toyka
- Department of Neurology, University of Würzburg, Germany
| | - C Burek
- Institute of Pathology, University of Würzburg, Germany
| | - A Rosenwald
- Institute of Pathology, University of Würzburg, Germany
| | | | | | - A Meager
- Biotherapeutics, National Institute for Biological Standards and Control, South Mimms, UK
| | - N Willcox
- Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, UK
| | - P Peterson
- Molecular Pathology, University of Tartu, Estonia
| | - A Marx
- Institute of Pathology, University Medical Centre Mannheim, University of Heidelberg, Germany
| |
Collapse
|
34
|
Viiri KM, Korkeamäki H, Kukkonen MK, Nieminen LK, Lindfors K, Peterson P, Mäki M, Kainulainen H, Lohi O. SAP30L interacts with members of the Sin3A corepressor complex and targets Sin3A to the nucleolus. Nucleic Acids Res 2006; 34:3288-98. [PMID: 16820529 PMCID: PMC1500868 DOI: 10.1093/nar/gkl401] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Histone acetylation plays a key role in the regulation of gene expression. The chromatin structure and accessibility of genes to transcription factors is regulated by enzymes that acetylate and deacetylate histones. The Sin3A corepressor complex recruits histone deacetylases and in many cases represses transcription. Here, we report that SAP30L, a close homolog of Sin3-associated protein 30 (SAP30), interacts with several components of the Sin3A corepressor complex. We show that it binds to the PAH3/HID (Paired Amphipathic Helix 3/Histone deacetylase Interacting Domain) region of mouse Sin3A with residues 120-140 in the C-terminal part of the protein. We provide evidence that SAP30L induces transcriptional repression, possibly via recruitment of Sin3A and histone deacetylases. Finally, we characterize a functional nucleolar localization signal in SAP30L and show that SAP30L and SAP30 are able to target Sin3A to the nucleolus.
Collapse
Affiliation(s)
- K. M. Viiri
- Paediatric Research Centre, University of Tampere Medical School and Tampere University HospitalTampere, Finland
| | - H. Korkeamäki
- Paediatric Research Centre, University of Tampere Medical School and Tampere University HospitalTampere, Finland
| | - M. K. Kukkonen
- Paediatric Research Centre, University of Tampere Medical School and Tampere University HospitalTampere, Finland
| | - L. K. Nieminen
- Paediatric Research Centre, University of Tampere Medical School and Tampere University HospitalTampere, Finland
| | - K. Lindfors
- Paediatric Research Centre, University of Tampere Medical School and Tampere University HospitalTampere, Finland
| | - P. Peterson
- Molecular Pathology, University of TartuTartu, Estonia
| | - M. Mäki
- Paediatric Research Centre, University of Tampere Medical School and Tampere University HospitalTampere, Finland
| | - H. Kainulainen
- Institute of Medical Technology and Tampere University HospitalTampere, Finland
- Department of Biology of Physical Activity, University of JyväskyläFinland
| | - O. Lohi
- Paediatric Research Centre, University of Tampere Medical School and Tampere University HospitalTampere, Finland
- To whom correspondence should be addressed. Tel: +358 3 355 184 05; Fax: +358 3 355 184 02;
| |
Collapse
|
35
|
Peterson P, Zwitter M, Krzakowski M, Wenczl M, Tzekova V, Ramlau R, Ciuleanu T, Liepa A, Zielinski C, Brodowicz T. Delay in time to worsening of symptoms (TWS) of advanced non-small cell lung cancer (NSCLC) using gemcitabine (gem) maintenance therapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7140 Background: Palliation of disease-related symptoms is an important clinical benefit. For advanced disease, this may be relief or delay of worsening of symptoms. Since benefit evaluation in clinical trials is usually focused on radiological assessments, development is needed to establish symptom improvement as an efficacy endpoint. Methods: To determine if gem maintenance therapy delayed the worsening of symptoms, retrospective analyses were performed using symptom data reported by patients (pts) with advanced NSCLC from a randomized trial of gem plus cisplatin followed by gem maintenance therapy plus best supportive care (GBSC) or best supportive care (BSC) (Krzakowski, ASCO 2004). Pts rated 6 symptoms using the Lung Cancer Symptom Scale (LCSS) at baseline and every cycle. Symptom worsening was retrospectively defined as a 15-mm increase in the severity score for any symptom (based on 100-mm scales) from randomization (start of maintenance therapy). Analyses were repeated for 10- and 20-mm increases. Data were analyzed using Kaplan-Meier (KM) plots and Cox regression, with censoring at the last LCSS for pts with no worsening. Results: At randomization, 73% were stage IV and 48% had Karnofsky performance status >80. Of the 206 pts randomized, 171 were included in the symptom analyses. Although not significant, the KM plot for TWS based on the 15-mm definition (defn) showed a separation between arms in favor of GBSC beginning ∼2.5 months after randomization (p = 0.24, HR = 0.79). TWS results for the 20-mm defn were significant in favor of GBSC (p = 0.013, HR = 0.59). When the same analysis was applied to individual symptoms, all symptoms showed the same numerical trend (HR<0.77) in favor of GBSC, with significant TWS advantage for GBSC (HR<0.56) for appetite loss and fatigue (15- and 20-mm defn) and for pain (20-mm defn). Additional analyses suggested a strong correlation between TWS and time to progressive disease. Conclusions: In addition to prolonging time to disease progression, gem maintenance therapy delays pt-reported worsening of symptoms. Correlation of TWS with time to progression suggests that delayed TWS may be a clinical benefit of delayed onset of progressive disease. [Table: see text]
Collapse
Affiliation(s)
- P. Peterson
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - M. Zwitter
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - M. Krzakowski
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - M. Wenczl
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - V. Tzekova
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - R. Ramlau
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - T. Ciuleanu
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - A. Liepa
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - C. Zielinski
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| | - T. Brodowicz
- Eli Lilly and Company, Indianapolis, IN; Institute of Oncology, Ljubljana, Slovenia; M. Sklodowska-Curie Memorial, Warsaw, Poland; Markusovszky Teaching Hospital, Szombathely, Hungary; University Hospital, Sofia, Bulgaria; Regional Center of Lung Diseases, Poznan, Poland; Oncology Institute Ion Chiricuta, Cluj Napoca, Romania; Medical University Vienna, Vienna, Austria
| |
Collapse
|
36
|
Fossella FV, Berry DA, Adachi S, McAndrews P, Peterson P. Survival in previously treated advanced NSCLC: Pemetrexed versus best supportive care (BSC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17015 Background: Patients with advanced NSCLC who progress following initial treatment have several approved secondary treatment options including single agent intravenous chemotherapy (docetaxel or pemetrexed) and an oral EGFR tyrosine kinase inhibitor (erlotinib). Docetaxel and erlotinib were shown in randomized trials to have an overall survival (OS) advantage over BSC. On the other hand, pemetrexed was approved based on a randomized trial (JMEI) in which it showed clinically equivalent survival to docetaxel. Investigators felt that it was not ethical to compare pemetrexed to BSC because docetaxel was approved in that setting. However, indirect comparisons of pemetrexed with BSC are possible and are legitimate statistically. Methods: We used summary data from JMEI and TAX317(b) in the analysis. Studies BR21 and ISEL provide relevant data from recent trials with a BSC arm. We based comparisons on the logarithms of these HRs and their variances in proportional hazards models, accounting for interstudy variability. Results: Patients in these studies had similar prognostic characteristics. Docetaxel in TAX317(b) showed a significant survival benefit over BSC (HR = 0.56, 95% CI 0.35–0.88). In JMEI, the pemetrexed over docetaxel HR was 0.99 (95% CI 0.82–1.20). The HR of pemetrexed over BSC for survival was 0.55 (95% CI 0.33–0.90). The similarity of median OS for the placebo (or BSC) arms of studies TAX317(b), BR21 and ISEL supports the above analysis. Conclusions: In comparison with BSC pemetrexed lowers the hazard of mortality in previously treated advanced NSCLC by an estimated 45% (95% CI 10%-67%). [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- F. V. Fossella
- M. D. Anderson Cancer Center, Houston, TX; Eli Lilly and Company, Indianapolis, IN
| | - D. A. Berry
- M. D. Anderson Cancer Center, Houston, TX; Eli Lilly and Company, Indianapolis, IN
| | - S. Adachi
- M. D. Anderson Cancer Center, Houston, TX; Eli Lilly and Company, Indianapolis, IN
| | - P. McAndrews
- M. D. Anderson Cancer Center, Houston, TX; Eli Lilly and Company, Indianapolis, IN
| | - P. Peterson
- M. D. Anderson Cancer Center, Houston, TX; Eli Lilly and Company, Indianapolis, IN
| |
Collapse
|
37
|
Yazwinski TA, Williams JC, Smith LL, Tucker C, Loyacano AF, Derosa A, Peterson P, Bruer DJ, Delay RL. Dose determination of the persistent activity of moxidectin long-acting injectable formulations against various nematode species in cattle. Vet Parasitol 2006; 137:273-85. [PMID: 16481112 DOI: 10.1016/j.vetpar.2006.01.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2005] [Revised: 01/09/2006] [Accepted: 01/15/2006] [Indexed: 11/19/2022]
Abstract
The effectiveness, safety and production-enhancing benefit (improved weight gains) of moxidectin long-acting injection given subcutaneously in the ear at the rates of 0.75, 1.0 and 1.5mg/kg bw were evaluated in three studies under common protocol. The only adverse reaction to treatment was a mild (<2 tablespoons in volume), and for the most part transient (<28 days for the treatment rate of 1.0mg/kg bw) injection site swelling as noted in a minority of the animals (12.2% of the animals treated at the rate of 1.0mg/kg bw). Regardless of study site, post-treatment interval or dose rate, average daily gains were improved over control cattle by approximately 33%. Reductions in strongyle EPG counts relative to controls were > or = 90% for all dose rates of moxidectin for a post-treatment period of 42 days (Wisconsin), 84 days (Arkansas) and 140 days (Louisiana). In Arkansas and Louisiana, the majority (>80%) of post-treatment strongyle eggs, as determined by coproculture, were Cooperia spp. As determined by sequential necropsies, periods of continuous, post-treatment protection (> or = 90% efficacy in at least two out of three studies) for moxidectin long-acting injection given at the rate of 1.0 mg/kg bw were 90 days (adult Haemonchus spp.), 120 days (Dictyocaulus viviparus and adult Ostertagia and Oesophagostomum) and 150 days (Ostertagia spp. EL4).
Collapse
Affiliation(s)
- T A Yazwinski
- Department of Animal Science, University of Arkansas, Fayetteville, AR 72701, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Pitkänen J, Rebane A, Rowell J, Murumägi A, Ströbel P, Möll K, Saare M, Heikkilä J, Doucas V, Marx A, Peterson P. Cooperative activation of transcription by autoimmune regulator AIRE and CBP. Biochem Biophys Res Commun 2005; 333:944-53. [PMID: 15964547 DOI: 10.1016/j.bbrc.2005.05.187] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2005] [Accepted: 05/25/2005] [Indexed: 11/18/2022]
Abstract
Autoimmune regulator (AIRE) is a transcriptional regulator that is believed to control the expression of tissue-specific genes in the thymus. Mutated AIRE is responsible for onset of the hereditary autoimmune disease APECED. AIRE is able to form nuclear bodies (NBs) and interacts with the ubiquitous transcriptional coactivator CBP. In this paper, we show that CBP and AIRE synergistically activate transcription on different promoter reporters whereas AIRE gene mutation R257X, found in APECED patients, interferes with this coactivation effect. Furthermore, the overexpression of AIRE and CBP collaboratively enhance endogenous IFNbeta mRNA expression. The immunohistochemical studies suggest that CBP, depending on the balance of nuclear proteins, is a component of AIRE NBs. We also show that AIRE NBs are devoid of active chromatin and, therefore, not sites of transcription. In addition, we demonstrate by 3D analyses that AIRE and CBP, when colocalizing, are located spatially differently within AIRE NBs. In conclusion, our data suggest that AIRE activates transcription of the target genes, i.e., autoantigens in collaboration with CBP and that this activation occurs outside of AIRE NBs.
Collapse
Affiliation(s)
- J Pitkänen
- Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson P, Gandara DR. Randomized phase III trial of gemcitabine/cisplatin (GC) and protein kinase C α (PKCα) antisense oligonucleotide aprinocarsen in patients (pts) with advanced stage non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Paz-Ares
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - J.-Y. Douillard
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - P. Koralewski
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - C. Manegold
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - E. F. Smit
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - J. M. Reyes
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - G. C. Chang
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - W. J. John
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - P. Peterson
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| | - D. R. Gandara
- Servicio de Oncología Médica Doce de Octubre Univ, Madrid, Spain; Ctr René Gauducheau, Saint Herblain, France; Wojewodzki Szpital Specjalistyczny, Krakow, Poland; Univ of Heidelberg, Medcl Ctr, Mannheim, Germany; VU Univ Medcl Ctr, Amsterdam, The Netherlands; Inst de Ontología, Clínica Las Condes, Santiago, Chile; Taichung Veterans Gen Hosp, Taichung, Taiwan Republic of China; Eli Lilly & Co, Indianapolis, IN; Univ of CA Davis Cancer Ctr, Sacramento, CA
| |
Collapse
|
40
|
Abstract
Infant botulism causes acute bulbar dysfunction, weakness, and respiratory failure in infants living in endemic regions of the United States. Until Food and Drug Administration approval of botulism immune globulin (BIG) in October 2003, management of infant botulism had changed little since the 1970s. Currently, IV therapy with BIG is advised to shorten the duration and diminish the potential complications of the disorder. This review describes two decades of experience with infant botulism and provides a contemporary perspective on the role and benefit of BIG.
Collapse
Affiliation(s)
- J A Thompson
- Division of Pediatric Neurology, Department of Pediatrics, The University of Utah, Primary Children's Medical Center, Salt Lake City, UT, USA.
| | | | | | | | | | | | | |
Collapse
|
41
|
Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005; 44:1026-31. [PMID: 15870150 DOI: 10.1093/rheumatology/keh673] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE To assess the efficacy and safety of the fully human recombinant monoclonal anti-TNF antibody adalimumab in routine clinical practice, including comparison of patients with and without previous anti-TNF exposure. METHODS We prospectively studied the outcome of 70 rheumatoid arthritis patients treated with adalimumab in normal clinical practice. The primary outcome measures were Disease Activity Score 28 (DAS28), EULAR (European League Against Rheumatism) response and Health Assessment Questionaire (HAQ). RESULTS Seventy-seven per cent achieved a EULAR response (26% good, 51% moderate) and 19% were in remission. The mean decrease in DAS28 was 2.1 (6.3-4.2; P<0.001). The mean decrease in HAQ score was 0.34 (2.07-1.73; P<0.001), 66% achieving a clinically significant decrease of greater than 0.22. Twenty-three per cent stopped treatment because of side-effects (7%) or failure to respond (16%). Of the 26 patients who had previously tried 29 biologicals, 65% responded to adalimumab. There was no significant difference in the change in mean DAS (P = 0.69) or HAQ (P = 0.88) between groups with and without previous anti-TNF exposure. Of the 13 patients with previous secondary failure to infliximab, 77% responded to adalimumab. Patients with previous secondary failure had significantly better improvement in DAS (P = 0.023) than patients with previous primary failure. CONCLUSION Our clinical experience confirms that adalimumab is effective and safe in the treatment of RA. It also shows adalimumab is effective in patients with previous biological failures, particularly patients with secondary failure to infliximab.
Collapse
Affiliation(s)
- A N Bennett
- Department of Rheumatology, Thomas Guy House, Guy's Hospital, St Thomas Street, London SE1 9RT, UK
| | | | | | | | | | | |
Collapse
|
42
|
Mocofanescu A, Wang L, Jain R, Shaw K, Gavrielides A, Peterson P, Sharma M. SBS threshold for single mode and multimode GRIN fibers in an all fiber configuration. Opt Express 2005; 13:2019-2024. [PMID: 19495085 DOI: 10.1364/opex.13.002019] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We investigate stimulated Brillouin scattering (SBS) threshold in single mode and multimode fibers in an all fiber network. The pump is a single mode fiber pigtail attached to a diode. We find the theory and experiment agree for both single mode and multimode GRIN fibers. We modify the bulk SBS threshold equation for use with fibers by properly accounting for mode sizes and modal dispersion.
Collapse
|
43
|
Stjernberg-Salmela S, Pettersson T, Karenko L, Blazevic V, Nevala H, Pitkänen S, Peterson P, Ranki A. A novel tumour necrosis factor receptor mutation in a Finnish family with periodic fever syndrome. Scand J Rheumatol 2004; 33:140-4. [PMID: 15228183 DOI: 10.1080/03009740310004892] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE To report a novel mutation of the TNF receptor type 1 gene (TNFRSF1A) in a Finnish patient and her mother, both suffering from periodic fever. METHODS Soluble TNFRSF1A in serum was measured by enzyme-linked immunoabsorbancy, and induced TNFRSF1A shedding from monocyte cell surfaces was determined using fluorescence-activated cell sorter. Mutation detection was performed using PCR amplification and sequencing of the ten exons of TNFRSF1A. RESULTS Low levels of soluble TNFRSF1A were detected in both patients between attacks. Sequencing revealed a missense mutation in exon 3 in the second extracellular domain of TNFRSF1A, resulting in a substitution of cysteine with arginine at residue 73 (C73R), confirming the diagnosis of TNF receptor-associated periodic syndrome (TRAPS). We were unable to demonstrate a distinct TNFRSF1A shedding defect. CONCLUSION In patients of Nordic descent, affected by dominantly inherited recurrent fever, TRAPS is a diagnosis worthy of attention. All TNFRSF1A mutations hitherto described in the Nordic countries have been different.
Collapse
Affiliation(s)
- S Stjernberg-Salmela
- Department of Dermatology, Helsinki University Central Hospital, Helsinki, Finland
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Bennett AN, Peterson P, Sangle S, Hangartner R, Abbs IC, Hughes GRV, D'Cruz DP. Adult onset Still's disease and collapsing glomerulopathy: successful treatment with intravenous immunoglobulins and mycophenolate mofetil. Rheumatology (Oxford) 2004; 43:795-9. [PMID: 15039497 DOI: 10.1093/rheumatology/keh172] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
In this Grand Round we present a 32-yr-old African man who became severely ill after a 5-month history of weight loss, pyrexia, arthralgia, sweats and rash. He went on to develop pericarditis, pericardial effusion with tamponade, hepatomegaly with abnormal liver function tests, lymphadenopathy, massive proteinuria and required ventilatory, circulatory and renal support. The differential diagnosis was adult onset Still's disease, systemic lupus erythematosus (SLE), infection and lymphoma. Primary infection and lymphoma were excluded and he was treated, with dramatic success, with intravenous immunoglobulins (i.v.IG). Subsequent renal biopsy excluded SLE but confirmed collapsing glomerulopathy. The proteinuria improved dramatically following treatment with mycophenolate mofetil. We discuss some of the difficult diagnostic and management issues raised by this patient and the different uses and mechanisms of action of i.v.IG.
Collapse
Affiliation(s)
- A N Bennett
- The Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK
| | | | | | | | | | | | | |
Collapse
|
45
|
Peterson P, Pitkänen J, Sillanpää N, Krohn K. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity. Clin Exp Immunol 2004; 135:348-57. [PMID: 15008965 PMCID: PMC1808970 DOI: 10.1111/j.1365-2249.2004.02384.x] [Citation(s) in RCA: 81] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/12/2003] [Indexed: 02/06/2023] Open
Affiliation(s)
- P Peterson
- Institute of Medical Technology and University Hospital, Tampere, Finland.
| | | | | | | |
Collapse
|
46
|
Webster KE, O'Bryan MK, Aapola U, Crewther PE, Lyle R, Meachem SJ, Antonarakis SE, Hedger MP, Peterson P, De Kretser DM, Scott HS. 255.Dnmt3L: a coordinator of epigenetic modifications during spermatogenesis. Reprod Fertil Dev 2004. [DOI: 10.1071/srb04abs255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Spermatogenesis is a process with unique epigenetic requirements. The differentiation from diploid spermatogonia to haploid spermatozoa requires regulation of genomic imprint establishment, stage specific gene expression, meiotic division, and the histone-protamine transition. The methyltransferase regulator, Dnmt3L, is expressed during gametogenesis and is necessary for establishment of maternal methylation imprints in the oocyte. Targeted disruption of Dnmt3L does not appear to affect oogenesis, as mature oocytes are generated, however resultant heterozygous progeny die mid gestation due to biallelic expression of imprinted genes. Dnmt3L–/– males however show spermatogenic arrest. We found that this arrest occurs during prophase I of meiosis, with spermatocytes lost by both apoptosis and germ cell sloughing. A progressive degeneration ensues, resulting in a Sertoli cell phenotype. Electron microscopy of meiotic spermatocytes revealed that homologous chromosomes fail to align and form synaptonemal complexes. Furthermore, Dnmt3L–/– spermatocytes show abnormal methylation on paternally imprinted genes and abnormal global retention of histone acetylation, implicating Dnmt3L in histone deacetylase recruitment. Thus, during spermatogenesis, Dnmt3L is crucial for two distinct epigenetic modifications; imprint establishment and global histone deacetylation prior to homologous chromosome alignment. The latter defect is likely to affect the alignment of homologous chromosomes and trigger the pachytene checkpoint leading to spermatocyte death. Since Dnmt3L has no DNA methlytransferase or HDAC activity itself, we propose that Dnmt3L is essential for the coordination of epigenetic layers, at least during spermatogenesis.
Collapse
|
47
|
Abstract
The autoimmune regulator (AIRE) is a gene where mutations cause the recessively inherited disorder called autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) or autoimmune polyendocrinopathy syndrome type 1 (APS1). Variable combinations of autoimmune endocrine diseases such as Addison's disease, hypoparathyroidism, and type 1 diabetes characterize APECED. The AIRE protein has several domains indicative of a transcriptional regulator. AIRE contains two PHD (plant homeodomain) type zinc fingers, four nuclear receptor binding LXXLL motifs, a putative DNA-binding domain named SAND and, in addition, a highly conserved N-terminal domain similar to the homogenously staining region domain of the Sp100 protein. At the subcellular level, AIRE is expressed in nuclear dots resembling promyelocytic leukemia nuclear bodies, which are associated with several transcriptionally active proteins. AIRE is primarily expressed in thymic medullary epithelial cells and monocyte-dendritic cells in the thymus but also in a rare subset of cells in the lymph nodes, spleen and fetal liver. The disease, caused by mutations in AIRE, its function as a protein involved in transcription, and its restricted expression in cells important in negative selection, all together suggest that AIRE is a central protein in the maintenance of immune tolerance. In this review of the recent literature we discuss the results of these studies with particular attention on the AIRE expression pattern and its function as a transcriptional regulator, as well as the effects of patient mutations on the molecular characteristics of the protein.
Collapse
Affiliation(s)
- J Pitkänen
- Institute of Medical Technology, University of Tampere and Tampere Hospital, Finland
| | | |
Collapse
|
48
|
Smith A, Sprague M, Peterson P, Worley L, McKinney S, Warnock S, Hansen J. Detection of an acquired mutation in an HLA-A∗03 allele impairing gene expression in leukemia cells of a patient with all. Hum Immunol 2002. [DOI: 10.1016/s0198-8859(02)00482-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Abstract
Macaques are well suited for preclinical testing of biopharmaceutics due to reproductive and developmental similarities with humans. In order to characterize ontogeny of the immune system in this model, we studied lymphocyte and antigen-presenting cell populations in developing lymphoid tissues of rhesus macaque fetuses during the second and third trimesters [gestation days (GD) 75-145, term 165 days]. Systemic lymphoid tissues (thymus, spleen and lymph nodes, and intestinal tissue) were examined for morphology and cell surface markers by immunohistochemistry. Lymphocytes were further characterized by flow cytometry for differentiation markers. Splenic tissue from early second trimester fetuses was populated mainly by CD20+ B cells while the thymus contained large numbers of CD3+ T cells. In the late second trimester (day 80), approximately equal populations of B and T cells were present in both tissues and numerous dendritic cells (p55+) were present in the intestinal lamina propria. By the second trimester, the rhesus macaque fetal lymphoid system is well developed. Analysis of lymphoid organs from retinoic acid-treated fetuses indicated that the T-cell (thymus)-dependent compartment of the spleen white pulp in specimens with thymic aplasia showed a reduction in size and proportion of CD3+ T cells compared to controls. Our findings indicate that RA-induced thymic defects result in disrupted development of the splenic T-cell-dependent compartment.
Collapse
Affiliation(s)
- A G Hendrickx
- California Regional Primate Research Center, University of California, Davis, California 95616-8542, USA.
| | | | | |
Collapse
|
50
|
Haakansson P, Kamensky I, Sundqvist B, Fohlman J, Peterson P, McNeal CJ, Macfarlane RD. Iodine-127-plasma desorption mass spectrometry of insulin. J Am Chem Soc 2002. [DOI: 10.1021/ja00374a053] [Citation(s) in RCA: 92] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|